1. Japan Stocks

  2. •

    Consumer non-durables

  3. •

    Food: specialty/candy
Ajinomoto Co., Inc.

Ajinomoto Co., Inc.

5,046.00
JPY
-232.00
(-4.40%)
2.94TMarket Cap
Nov 09Next Earn
Ajinomoto Co., Inc.
TSE:2802
(Tokyo Stock Exchange)

Recent

price

5,046.00

P/E

ratio

- -

div

yld

0.00%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
865.32
878.54
756.92
774.77
850.22
977.3
954.21
980.44
1,005.86
1,003.42
976.99
1,058.1
1,271.29
691.5
1,519.61
1,627.05
- -
Revenue per Share
21.78
30.64
37.17
34.33
39.27
60.62
46.4
52.88
26.81
17.18
54.18
69.71
87.99
41.86
69.77
138.36
- -
Basic EPS, GAAP
49.15
32.47
17.49
7.95
50.95
61.95
19.86
42.82
39.04
29.93
72.59
59.71
41.71
46.15
113.99
- -
- -
Free Cash Flow per Basic Share
8
8.07
8.15
10.13
10.01
13.59
15.08
15.01
16.66
16.01
15.98
25.11
29.59
18.45
38.86
- -
- -
Dividend per Share
435.81
447.29
502.19
501.14
549.72
524.48
541.45
564.22
556.96
491.6
565.41
640.25
726.12
795.09
751.01
804.24
- -
Book Value per Share
388.88
403.56
471.61
457.07
451.16
408.88
403.5
411.43
413.28
346.38
412.06
483.53
576.84
563.23
539.72
578.58
- -
Tangible Book Value per Share
1,396
1,363
1,301
1,228
1,184
1,176
1,144
1,137
1,108
1,096
1,097
1,086
1,069
2,081
1,007
973
1,003
Basic Weighted Avg Shares
1,207,695
1,197,313
984,967
951,359
1,006,630
1,149,427
1,091,195
1,114,784
1,114,308
1,100,039
1,071,453
1,149,370
1,359,115
1,439,231
1,530,556
1,583,719
- -
Sales/Revenue/Turnover
5.74
6.06
7.23
6.5
7.4
8.57
7.43
6.7
4.86
4.66
9.32
10.75
10.64
9.86
7.03
12.08
- -
Operating Margin (%)
54,330
48,220
44,728
47,335
45,577
50,852
46,273
51,783
52,485
61,986
63,045
66,234
71,820
78,298
86,461
- -
- -
Depreciation Expense
30,400
41,754
48,373
42,159
46,495
71,292
53,065
60,124
29,698
18,837
59,416
75,725
94,065
87,121
70,272
134,675
- -
Net Income, GAAP
25.95
34
45.36
31.66
29.95
20.89
25.05
18.97
32.35
41.77
32.59
34.49
28.47
28.17
25.44
26.03
- -
Effective Tax Rate (%)
2.52
3.49
4.91
4.43
4.62
6.2
4.86
5.39
2.67
1.71
5.55
6.59
6.92
6.05
4.59
8.5
- -
Profit Margin (%)
298,091
302,920
330,533
312,680
231,696
374,129
312,651
324,049
299,411
203,335
248,830
256,788
275,893
208,063
316,710
255,107
- -
Working Capital
109,271
104,837
81,434
104,428
74,073
243,226
298,964
309,711
306,636
273,685
291,519
271,281
239,244
254,224
416,207
380,922
- -
LT Debt
650,291
650,158
691,710
655,505
725,331
680,727
690,673
720,613
685,960
592,070
667,846
739,744
822,968
884,448
813,273
844,275
- -
Total Equity
6.46
6.08
4.82
5.17
5.96
8.28
6.29
6.07
3.47
2.86
6.85
7.8
9.72
8.56
6.48
11.47
- -
Return on Invested Capital (%)
3.41
4.8
5.39
4.5
4.51
7.05
4.49
5.58
2.43
1.36
5.8
7.44
9.12
6.65
5.43
10.53
- -
Return on Capital (%)
5.02
6.88
7.8
6.85
7.47
11.31
8.66
9.57
4.75
3.28
10.25
11.59
12.92
11
9
17.75
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'25
Mar'25
Jun'26
ST Debt
48,972
39,146
- -
LT Borrowings
442,401
416,207
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,008
994
980
Market Capitalization
2,794,428
2,941,932
3,829,839

Working Capital

JPY

•

in mil. unless spec.
Sep'25
Mar'25
Jun'26
Total Current Assets
705,370
701,298
- -
Cash, Cash Equivalents & STI
196,124
182,766
- -
Accounts Receivable, Net
175,884
174,136
- -
Inventories
303,879
286,952
- -
Total Current Liabilities
333,881
384,588
- -
Payables & Accruals
- -
- -
- -
ST Debt
48,972
39,146
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.53%
5.05%
3.81%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
23.26%
23.32%
91.65%
Sales/Revenue/Turnover
3.44%
8.25%
3.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1,530,556
2026
- -
- -
- -
- -
1,583,719
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
69.77
2026
- -
- -
- -
- -
138.36
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
38.86
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
PepsiCo, Inc. (NASDAQ:PEP)
Britannia Industries Ltd (NSE:BRITANNIA)
Tata Consumer Products Limited (NSE:TATACONSUM)
Ulker Biskuvi Sanayi A.S. (BIST:ULKER)
Mondelez International, Inc. (NASDAQ:MDLZ)
The Hershey Company (NYSE:HSY)
Business
Ajinomoto Co., Inc. manufactures and markets a broad range of food products, seasonings, amino acids, pharmaceuticals, and functional materials worldwide. Founded in 1909 and headquartered in Tokyo, Japan, the company operates through three primary segments: seasonings and foods, which includes umami seasonings such as AJI-NO-MOTO monosodium glutamate, processed foods, frozen foods, dry soup mixes, edible oils, beverages, and dairy products; healthcare, encompassing amino acid infusions, enteral nutrition, biopharmaceutical contract development and manufacturing services, and gene therapy-related offerings; and functional materials, featuring Ajinomoto build-up film (ABF) for semiconductors, specialty chemicals, animal nutrition products, and moisturizing agents like AJIDEW and Amisoft. It serves consumer markets, food manufacturers including Nestle, and industrial clients across Asia, the Americas, Europe, the Middle East, Africa, and other regions through dozens of subsidiaries such as Ajinomoto North America, Ajinomoto Philippines Corporation, and Ajinomoto India Private Limited. Recent developments include the October 2025 licensing agreement with Astellas Pharma Inc. for biopharmaceutical development and manufacturing technology; investments in v2food Pty Ltd for sustainable foods in August 2025, Somite Therapeutics Inc. for AI-driven iPS cell differentiation in June 2025, and Enhanced Medical Nutrition Inc. for surgical nutrition in March 2025; the announcement to build a new factory at Ajinomoto Philippines Corporation in August 2025; development of culture media supplements with Forge Biologics to enhance gene therapy productivity in November 2025 following its prior acquisition; plans to sell its stake in Ajinomoto Althea, a U.S. aseptic fill-finish CDMO, in April 2025; and ongoing share repurchase programs alongside organizational changes in February 2025.

Company News

Company News APIChatGPT

  • wsj.com

    AI Needs Ajinomoto's Film, But Its CEO Won't Raise Prices Just Because

  • seekingalpha.com

    Ajinomoto Q4 Earnings: The Good And The Bad